Vape 10-Q 24 May 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2016	May. 24, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Vape Holdings, Inc.
Entity Central Index Key	1,455,819
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		366,873,168

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Current assets:
Cash	$ 52,111	$ 273,904
Accounts receivable	67,320	72,401
Inventory	$ 274,748	194,937
Prepaid inventory		64,079
Other current assets	$ 27,169	40,679
Deferred financing costs		107,908
Total current assets	$ 421,348	753,908
Fixed assets, net of accumulated depreciation	84,269	118,327
Trademarks	$ 123,150	123,150
Deferred financing costs, long-term		12,067
TOTAL ASSETS	$ 628,767	1,007,452
Current liabilities:
Accounts payable	297,350	115,938
Accrued expenses	$ 289,578	207,609
Customer deposits		$ 1,275
Related party convertible notes payable	$ 300,000
Convertible notes payable, net of unamortized discount of $426,118 and $153,096, respectively $426,118 and $153,096, respectively	298,181	$ 522,396
Related party notes payable	15,000
Derivative liabilities	3,788,661	$ 1,672,726
Warrant liability	7,422	31,401
Total current liabilities	4,996,192	2,551,345
Long term liabilities:
Convertible notes payable, long-term, net of unamortized discount of $109,065 and $655,607, respectively	$ 26,541	300,156
Related party notes payable, long-term		265,000
Other liabilities, long-term		12,235
Total liabilities	$ 5,143,710	$ 3,128,736
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.00001 par value - 100,000,000 authorized;500,000 outstanding at December 31, 2015 and September 30, 2015
Common stock, $0.00001 par value - authorized 1,000,000,000 shares; 244,570,234 issued at March 31, 2016, 265,479,609 outstanding at March 31, 2016 and 19,896,521 issued at September 30, 2015, 19,455,896 outstanding at September 30, 2015	$ 2,655	$ 192
Common stock to be issued	90,000
Additional paid-in capital	29,332,209	$ 26,412,800
Prepaid stock-based compensation	(100,000)
Treasury stock, 1,025,625 and 690,625 shares at March 31, 2016 and September 30, 2015, respectively	(372,601)	$ (367,531)
Accumulated deficit	(33,467,206)	(28,166,745)
Total stockholders' deficit	4,514,943	(2,121,284)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 628,767	$ 1,007,452

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares outstanding	500,000	500,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	244,570,234	19,896,521
Common stock, shares outstanding	265,479,609	19,455,896
Treasury Stock, Shares	1,025,625	690,625
Unamortized discount convertible notes payable, current	$ 87,121	$ 153,096
Unamortized discount convertible notes payable, non current	$ 19,159	$ 655,607

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue		$ 487,400	$ 415,259	$ 734,228	$ 801,902
Cost of revenue		449,306	297,642	654,715	447,528
Gross profit		38,094	117,617	79,513	354,374
Operating expenses:
Sales and marketing [A]	[1]	126,527	296,058	258,372	365,338
Research and development		11,099	200	46,698	52,053
General and administrative [B]	[2]	255,297	398,343	560,849	1,373,050
Total operating expenses		392,923	694,601	865,919	1,790,441
Operating loss		(354,829)	(576,984)	(786,406)	(1,436,067)
Other income (expense):
Interest expense		(540,942)	(93,488)	(1,318,885)	(171,478)
Interest expense - related party		(4,778)	(6,587)	(9,016)	(152,150)
Change in derivative liabilities		$ (1,996,998)	414,654	$ (2,126,858)	1,824,479
Gain on settlement			367,531		625,461
Loss on debt extinguishment, net			$ (19,981)		$ (19,981)
Excess of fair value of embedded conversion features		$ (1,058,496)		$ (1,058,496)
Total other income (expense), net		(3,601,214)	$ 662,129	(4,513,255)	$ 2,106,331
Income (loss) before provision for income taxes		$ (3,956,043)	$ 85,145	(5,299,661)	670,264
Provision for income taxes				800	2,209
Net income (loss)		$ (3,956,043)	$ 85,145	$ (5,300,461)	$ 668,055
Net loss available to common shareholders:
Income (loss) per common share - basic		$ (0.03)	$ 0.02	$ (0.04)	$ 0.09
Income (loss) per common share - diluted		$ (0.03)	$ 0.01	$ (0.04)	$ 0.07
Weighted average shares - basic		116,275,351	11,148,666	148,949,185	10,918,103
Weighted average shares - diluted		116,275,351	13,871,488	148,949,185	13,605,046
[1]	Stock-based compensation was $2,457 and $0, and $34,800 and $140,886 for the three and six months ended March 31, 2016 and 2015, respectively.
[2]	Stock-based compensation was $465 and $0, and $35,265 and $636,683 for the three and six months ended March 31, 2016 and 2015, respectively.

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Stock-based compensation			$ 36,000	$ 826,052
Sales and marketing [Member]
Stock-based compensation	$ 2,457	$ 0	34,800	140,886
General and administrative [Member]
Stock-based compensation	$ 465	$ 0	$ 35,265	$ 636,683

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - 6 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock to be Issued	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Prepaid Stock-based Compensation	Treasury Stock	Series A Preferred stock
Balance at Sep. 30, 2015	$ (2,121,284)		$ 192	$ 26,412,800	$ (28,166,745)		$ (367,531)
Balance, Shares at Sep. 30, 2015			19,205,896					500,000
Conversion of notes payable and accrued interest	2,653,405		$ 2,196	2,651,209
Conversion of notes payable and accrued interest, Shares			219,527,208
Conversion of unpaid wages	95,708		$ 41	95,667
Conversion of unpaid wages, Shares			4,138,888
Common stock issued for services	31,689		$ 14	31,675
Common stock issued for services, Shares			1,442,617
Common stock issued for bonuses	$ 36,000		$ 15	35,985
Common stock issued for bonuses, Shares			1,500,000
Surrender of common stock			$ (3)	$ 5,073			(5,070)
Surrender of common stock, Shares			(335,000)
Common stock to be issued	$ 90,000	$ 90,000
Common stock to be issued, Shares
Common stock issued to CEO			$ 200	$ 99,800		$ (100,000)
Common stock issued to CEO, Shares			20,000,000
Net income	$ (5,300,461)				$ (5,300,461)
Balance at Mar. 31, 2016	$ 4,514,943	$ 90,000	$ 2,655	$ 29,332,209	$ (33,467,206)	$ (100,000)	$ (372,601)
Balance, Shares at Mar. 31, 2016			265,479,609					500,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ (5,300,461)	$ 668,055
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	76,533	29,815
Accretion of debt discounts	1,041,921	$ 101,881
Excess of fair value of embedded conversion features	1,058,496
Fair value in excess of stock issued for conversion of notes payable and accrued interest	112	$ 122,909
Loss (gain) on change in derivative liabilities	$ 2,126,858	(1,824,479)
Gain on settlement		$ (625,461)
Forbearance and assignment settlements	$ 190,718
Loss on debt extinguishments, net		$ 19,981
Common stock issued for services	$ 31,689	36,769
Stock-based compensation	36,000	826,052
Changes in operating assets and liabilities:
Accounts receivable	5,081	(13,841)
Inventory	(15,732)	(60,598)
Other assets	13,510	10,673
Accounts payable	181,412	149,747
Accrued expenses	188,545	68,567
Net cash used in operating activities	(365,318)	(489,930)
Cash flows from investing activities:
Capital expenditures	$ (42,475)	(42,746)
Purchase of trademarks and pending patents		(9,105)
Net proceeds from settlement		62,930
Net cash provided by (used in) investing activities	$ (42,475)	$ 11,079
Cash flows from financing activities:
Net proceeds from common stock to be issued	90,000
Net proceeds from issuance of convertible notes payable	46,000	$ 835,000
Net proceeds from issuances of related party convertible notes payable	$ 50,000
Net proceeds from issuances of notes payable
Repayments on notes payable		$ (72,828)
Repayments on convertible notes payable		(40,000)
Repayments on related party convertible notes payable		(50,000)
Net cash provided by financing activities	$ 186,000	672,172
Net change in cash	(221,793)	193,321
Cash, beginning of period	273,904	48,370
Cash, end of period	$ 52,111	241,691
Cash paid during the period for:
Interest		18,788
Taxes	$ 800	2,209
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest	$ 2,653,405	$ 370,260

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2016
Description of Business and Summary of Significant Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BUSINESS Vape Holdings, Inc. (“VAPE,” the “Company,” “we,” “us,” “our,” “our company”) is a holding company with its primary focus in the manufacturing and distribution of healthy and sustainable vaporization products. The Company designs, markets and distributes ceramic vaporization products under a unique brand. The Company has introduced a nonporous, non-corrosive, chemically inert medical-grade ceramic vaporization element as a healthy, sustainable alternative to traditional titanium and quartz vaporization materials, as well as lower-grade ceramic found in traditional electronic cigarettes and vaporizers. This material can be used for a wide range of applications, including stand-alone vaporization products and "E-cigs." Electronic cigarettes come in a variety of designs ranging from those that look vastly like traditional cigarettes, to larger vaporizer units which are capable of vaporizing liquid with varying viscosity. The process of vaporization is believed to eliminate the smoke, tar, ash, and other byproducts of traditional smoking by utilizing lower temperatures in a controlled electronic environment. HIVE CERAMICS HIVE Ceramics (“HIVE”) is the premier brand under the VAPE umbrella. HIVE manufactures and distributes a proprietarily blended ceramic vaporization element for torched, electronic and portable vaporizers with countless design and product crossover capabilities in existing and emerging markets. HIVE is dedicated to bringing the healthiest and cleanest vaporization experience possible to the market. The HIVE product line currently consists of over 15 distinct ceramic elements, including the 2 piece domeless, domeless direct inject, and HIVE’s signature domeless elements covering 10mm, 14mm and 18mm applications as well as regular elements, the HIVE Flower Cup, the HIVE Carb Cap, HIVE Stinger Dabber, the 14mm HIVE x Quave - Club Banger, the HIVE x Brothership Honey Bucket and the HIVE x D-Nail 16mm and 20mm attachments. The Company intends to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has created or acquired and continues in the process of creating and/or acquiring proprietary vaporizers and e-cigarettes, and various trademarks, patents and copyrights for brands which are developed or in development. The Company is actively engaged in improving and expanding lines of branded products through business alliances and acquisitions, as well as developing its branded retail business expansion. VAPE and its business units are organized and directed to operate strictly in accordance with all applicable state and federal laws. REVIVAL PRODUCTS On December 28, 2015, the Company created a new wholly-owned subsidiary, Revival Products, LLC (“Revival”), which is in the business of portable vaporization devices. Revival will sell disposable cartridges that complement HIVE Ceramic’s product lines utilizing its sales and distribution channels and via its own designated e-commerce site at www.revivalvapes.com BETTERCHEM On July 1, 2015, the Company entered into a Share Exchange Agreement with BetterChem Consulting, Inc. (“BetterChem”), a Pennsylvania corporation, and its sole shareholder and the Company’s current Chief Science Officer Dr. Mark Scialdone (“Dr. Scialdone”), whereby the Company acquired a controlling 80% interest in BetterChem from Dr. Scialdone in exchange for up to 400,000 shares of the Company’s restricted common stock. In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem. The Share Exchange Agreement transaction closed concurrently with its execution on July 1, 2015 and was approved by Unanimous Written Consent of the Board of Directors (the “Board”) of the Company on the same date. At closing, the Company issued 250,000 shares of its common stock valued at $67,500 to BetterChem. BetterChem had no identifiable assets and liabilities upon closing, and no significant revenues. On January 12, 2016, the Company unwound the transaction and curtailed the subsidiary’s operations in order to reduce overhead costs and focus on HIVE Ceramics. An impairment of the acquisition of BetterChem of $69,250 was recorded during the year ended September 30, 2015. VAPE is organized and directed to operate strictly in accordance with all applicable state and federal laws. GOING CONCERN VAPE’s consolidated financial statements reflect a net loss of $5,300,461 during the six months ended March 31, 2016. As of March 31, 2016, we had cash of $52,111 and a working capital deficit of $4,574,844. VAPE has suffered an accumulated deficit of $33,467,206 and during the six months ended March 31, 2016, the Company took steps to curtail its Offset, HIVE Glass and HIVE Supply business lines to focus more on consumer vaporization products including the launch of “Revival” discussed above. The Company also curtailed its THE HIVE retail store in order to reduce overhead costs and focus on HIVE Ceramics. Moreover, the Company curtailed its exploration into providing real estate, management and consulting solutions to the legal cannabis industry in states where such cannabis cultivation and extraction is legal. The Company was never able to execute on any of these plans and ultimately determined that the Company’s capital reserves for such projects as well as the risks inherent in each project due to the current regulatory environment surrounding the cannabis industry made this line of business too difficult to pursue. All of which have resulted in losses and opportunity costs. In addition, the ongoing need to obtain financing to fund operations also raise substantial doubt about the ability of Vape to continue as a going concern. Management is skeptical that VAPE will obtain funding for operations for the foreseeable future; there are no assurances that the Company will obtain such funding. VAPE’s financial statements do not include any adjustments to reflect the possible effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability to continue as a going concern. See Note 10 for subsequent events regarding financing activities. VAPE is currently involved in litigation with 2 convertible promissory note holders seeking the specific performance of VAPE’s issuance of shares underlying denied conversion notices. VAPE is also currently negotiating with a third noteholder threatening similar litigation. VAPE shall vigorously defend the lawsuits; however, if these noteholders are allowed to convert their respective notes VAPE shareholders will experience substantial dilution.

Accounting Policies and Basis o

Accounting Policies and Basis of Presentation	6 Months Ended
	Mar. 31, 2016
Accounting Policies and Basis of Presentation [Abstract]
ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2. ACCOUNTING POLICIES AND BASIS OF PRESENTATION BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year. CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Revival and Nouveau after elimination of all material inter-company accounts and transactions. USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the convertible notes payable warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2016 and September 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at March 31, 2016: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 52,111 $ - $ - $ 52,111 Total assets measured at fair value $ 52,111 $ - $ - $ 52,111 Liabilities Derivative instruments $ - $ 3,796,083 $ - $ 3,796,083 Total liabilities measured at fair value $ - $ 3,796,083 $ - $ 3,796,083 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 1,704,127 $ - $ 1,704,127 Total liabilities measured at fair value $ - $ 1,704,127 $ - $ 1,704,127 CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Three (3) customers accounted for 70% of our accounts receivable as of March 31, 2016. One (1) customer accounted for 37% of our accounts receivable as of September 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 73% and 74% of our purchases during the three and six months ended March 31, 2016. Two (2) suppliers and one (1) supplier accounted for 79% and 70% of our purchases during the three and six months ended March 31, 2015. The loss of these suppliers would have a significant impact on the Company’s financial results. REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is generally recorded when sales orders are shipped. INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired. FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is two (2) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life of the asset. IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three and six months ended March 31, 2016 and 2015, the Company did not record any impairment of its trademarks as its expected future cash flows are in excess of their carrying amounts. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and d evelopment costs include the research and development expenses related to prototypes of the Company’s products. During the three and months ended March 31, 2016 and 2015, research and development costs were $11,099 and $200, and $46,698 and $52,053, respectively. CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. Many of the conversion features embedded in the Company's notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. In these cases, we record the embedded conversion feature as a derivate instrument, at fair value. The embedded conversion features are recorded as discounts when the notes become convertible. The excess of fair value of the embedded conversion feature over the carrying value of the debt is recorded as an immediate charge to operations. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt using the effective interest method. The Company has lost the ability to increase the share reserves due to the significantly increased outstanding held by convertible noteholders and a shareholder vote is required to increase the authorized amount of shares the Company may issue. Further, the combination of limited capital and depleted share reserves have severely damaged the Company’s ability to find continued finance, properly run the Company, and proceed with business to include any mergers or acquisitions or any transactions that would require available stock. DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes. EARNINGS (LOSS) PER COMMON SHARE Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. In the event of losses, such common share equivalents are excluded as their effects are antidilutive. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three and six months ended March 31, 2016: For the Three Months Ended For the Six Months Ended March 31, March 31, 2016 2016 Series A Preferred stock 500,000 500,000 Common stock warrants 1,184,726 1,184,726 Convertible notes 631,560,394 631,560,394 633,245,120 633,245,120 The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders: For the Three Months For the Six Months March 31, March 31, Weighted average common shares outstanding used in calculating basic earnings per share 11,148,666 10,918,103 Effect of preferred stock 500,000 500,000 Effect of convertible notes payable 2,025,679 2,025,679 Effect of options and warrants 197,143 161,264 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,871,488 13,605,046 Net income as reported $ 85,145 $ 668,055 Add - interest on convertible notes payable 100,075 323,506 Net income available to common stockholders $ 185,220 $ 991,561 The Company excluded 751,250 and 502,500 options from the computation for the three and six months ended March 31, 2015, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method. STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the six months ended March 31, 2016 and 2015: Six Months Ended March, Stock Price at Grant Date Dividend Yield Exercise Price Risk Free Interest Rate Volatility Average Life 2016 n/a n/a n/a n/a n/a n/a 2015 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Prepaid stock-based compensation is recorded when shares are issued based on the value on the grant date, but vest over the contractual period at which time the prorated expense will be recorded. RECENT ACCOUNTING PRONOUNCEMENTS In April 2015, the FASB issued Accounting Standard Update ("ASU") 2015-03 Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be classified as a reduction to the carrying value of debt rather than a deferred charge, as is currently required. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented, and early adoption is permitted. The Company adopted the policy during the quarter ending March 31, 2016. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Fixed Assets

Fixed Assets	6 Months Ended
	Mar. 31, 2016
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 3. FIXED ASSETS The following is a summary of fixed assets as of March 31, 2016 and September 30, 2015: March 31, September 30, Molds and Tooling $ 218,490 $ 176,015 Leasehold improvements - 29,795 Accumulated depreciation (134,221 ) (87,483 ) $ 84,269 $ 118,327 During the six months ended March 31, 2016 and 2015, depreciation expense included in cost of revenue were $76,533 and $29,815, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Mar. 31, 2016
Accrued Expenses [Abstract]
Accrued expenses	NOTE 4. ACCRUED EXPENSES The following is a summary of accrued expenses as of March 31, 2016 and September 30, 2015: March 31, September 30, Accrued interest $ 120,529 $ 46,337 Accrued interest - related party 33,554 24,538 Accrued wages and taxes 121,122 112,322 Other 14,373 24,411 $ 289,578 $ 207,608 As of March 31, 2016, $25,000 for Kyle Tracey, $16,667 for Joe Andreae, $33,742 for Mike Cook, $11,055 for Allan Viernes, $11,055 for Benjamin Beaulieu, and $10,807 for Justin Braune are recorded in accrued wages.

Third Party Debt

Third Party Debt	6 Months Ended
	Mar. 31, 2016
Third Party Debt [Abstract]
THIRD PARTY DEBT	NOTE 5. THIRD PARTY DEBT CONVERTIBLE NOTES PAYABLE In connection with the Third Party Debt Conversions, each of the Company’s convertible noteholders is entitled to a “share reserve” per their agreements with the Company which entitle them to reserve a certain allotment of common stock out of the authorized but unissued common stock of the Company for future conversions of their notes. The Company is further obligated under the agreements to increase the Company’s authorized share count to accommodate for a sufficient amount of share reserves. Due to the declining market price of the Company’s common stock, the noteholders have reserve claims in excess of the common stock authorized at this time. The Company has determined at this time not to increase the authorized share count and is instead in discussions with its convertible noteholders about a consolidation, restructuring and/or buy-out of their notes to resolve these issues. The position taken by the Company may be considered a technical violation of their agreements with the noteholders but none of the noteholders have called a default under the terms of the notes at this time. The Company’s ability to issue common stock other than those presently allocated to noteholders is restricted during this time. The Company has lost the ability to increase the share reserves due to the significantly increased outstanding held by convertible noteholders and a shareholder vote is required to increase the authorized amount of shares the Company may issue. Further, the combination of limited capital and depleted share reserves have severely damaged the Company’s ability to find continued finance, properly run the Company, and proceed with business to include any mergers or acquisitions or any transactions that would require available stock. The Company has entered into discussions with its convertible noteholders about a consolidation, restructuring and/or buy-out of their notes to resolve these issues. The position taken by the Company may be considered a technical violation of their agreements with the noteholders but none of the noteholders have called a default under the terms of the notes at this time. The Company’s ability to issue common stock other than those presently allocated to noteholders is restricted during this time. The position taken by the Company may be considered a technical violation of their agreements with the noteholders but none of the noteholders have called a default under the terms of the notes at this time. The Company’s ability to issue common stock other than those presently allocated to noteholders is restricted during this time. The Company is currently involved in litigation with 2 noteholders seeking the specific performance of VAPE’s issuance of shares underlying denied conversion notices. VAPE is also currently negotiating with a third noteholder threatening similar litigation. If the noteholders are allowed to convert their respective notes VAPE shareholders will experience substantial dilution. The Company’s denial of the conversion notices has triggered a technical default on its convertible notes and have presented amounts due as current liabilities other than those subsequently converted and began accruing interest at their default interest rates. Further, our funding partner may not commit to purchasing the balance of the notes currently outstanding due to the declining stock market price of the Company’s common stock. Securities Purchase Agreement On December 3, 2014, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to sell, and the Investor agreed to purchase, an unsecured convertible promissory note (the “Note”) in the principal amount of $560,000 less an original issue discount (“OID”) of $50,000 and transaction expenses of $10,000 for a total purchase price of $500,000. The Company also paid a finder’s fee in the amount of $25,000 in connection with this transaction, which was recorded as a discount to the note as it was paid from the proceeds. The closing under the Securities Purchase Agreement occurred on December 3, 2014. The Company received $475,000 net proceeds after transactions costs. On December 10, 2015, the Company and the Investor entered into a forbearance agreement regarding the Investor’s convertible note and added $105,000 to the principal and charged to interest expense during the three months ended December 31, 2015. On February 26, 2016, the note was assigned to an accredited investor and $21,874 was added to the principal balance and charged to interest expense during the three and six months ended March 31, 2016. We amortized $8,333 and $8,333, and $16,667 and $11,111 of the original issue discount to interest expense during the three and six months ended March 31, 2016 and 2015, respectively. In addition, the Company recorded $45,940 in debt issuance costs as a discount on the note and amortized $7,656 and $7,657, and $15,312 and $10,209 to interest expense during the three and six months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, the Company had unamortized current and long-term debt issuance costs of $584 and $4,521, respectively. The original issue discount and debt issuance costs are amortized through the maturity date. On August 26, 2015, the Company and Investor entered into an Amendment whereby the conversion rate of the note was amended to 55% of the lowest price of the prior fifteen (15) trading days and conversion floor removed which amendment was triggered by the dilutive issuances of the August 2015 convertible note financing thereby entitling Investor to the lowest conversion rate granted during the year ended September 30, 2015 per the terms of the Securities Purchase Agreement. On August 26, 2015, the Company recorded the note as a derivative liability at fair value of $830,921, a derivative discount of $332,666, and the excess in fair value of $498,254 to loss on debt extinguishment. The total loss on debt extinguishment on this note was $582,254. During the three and six months ended March 31, 2016, the Company amortized $124,750 and $249,500 of the derivative discount to interest expense, recorded a loss on the change in fair value of the derivative liability of $655,426 and $862,269, and allocated the fair value of $424,596 and $663,353 of the conversions below to additional paid-in capital and a reduction in the derivative liability, respectively. As of March 31, 2016, the derivative liability was $711,523. Between October 2015 and March 31, 2016, the Company issued the following conversions for payment towards Investor: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 8, 2015 $ 21,000 $ - $ 21,000 $ 0.012 1,818,182 October 16, 2015 18,900 - 18,900 $ 0.012 1,636,364 October 22, 2015 25,800 - 25,800 $ 0.011 2,333,786 October 29, 2015 22,460 - 22,460 $ 0.011 2,031,660 November 11, 2015 33,500 - 33,500 $ 0.007 4,649,549 November 18, 2015 24,000 - 24,000 $ 0.006 4,195,804 November 30, 2015 30,000 - 30,000 $ 0.005 5,741,627 December 11, 2015 22,000 - 22,000 $ 0.002 9,090,909 December 28, 2015 22,500 - 22,500 $ 0.002 9,297,521 January 7, 2016 20,000 - 20,000 $ 0.002 10,101,010 January 20, 2016 12,500 - 12,500 $ 0.001 10,330,579 February 2, 2016 13,200 - 13,200 $ 0.001 10,909,091 March 2, 2016 10,627 - 10,627 $ 0.001 10,169,800 March 10, 2016 11,184 - 11,184 $ 0.001 10,702,619 March 17, 2016 8,272 - 8,272 $ 0.001 6,539,200 March 29, 2016 22,797 - 22,797 $ 0.002 12,191,000 March 31, 2016 22,347 - 22,347 $ 0.002 11,950,000 $ 341,087 $ - $ 341,087 123,688,701 Subsequent to quarter end, the Investor also enacted the following conversions: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued April 4, 2016 $ 25,140 $ - $ 25,140 $ 0.002 13,444,000 April 7, 2016 21,019 - 21,019 $ 0.002 11,240,000 April 13, 2016 35,664 - 35,664 $ 0.002 14,737,000 April 19, 2016 36,711 - 36,711 $ 0.002 15,170,000 April 20, 2016 18,244 - 18,244 $ 0.002 7,538,666 $ 136,778 $ - $ 136,778 62,129,666 As a result, as of March 31, 2016, $13,230 and $102,379, net of total unamortized discounts of $4,445 and $34,399 are classified as current and long-term on the accompanying consolidated balance sheet. As of March 31, 2016, there is $27,869 in accrued interest expense related to this note and the Company recorded $9,328 and $14,000, and $17,924 and $18,356 in interest expense during the three and months ended March 31, 2016 and 2015, respectively. $2M Securities Purchase Agreement On February 10, 2015, the Company entered into a securities purchase agreement (the “February 2015 Securities Purchase Agreement”) with an accredited investor pursuant to which the Company agreed to sell, and the investor agreed to purchase, an unsecured convertible promissory note (the “$2M Note”) in the principal amount of $2,000,000 less an OID of $182,000 and transaction expenses of $10,000 for a total purchase price of $1,808,000. The closing under the February 2015 Securities Purchase Agreement occurred on February 10, 2015. During the year ended September 30, 2015, the Company received $800,000 toward the $2M Note with an original issue discount of $148,600 and transaction costs for net proceeds of $651,395, respectively. On February 23, 2016, the note was assigned to an accredited investor the same accredited investor as the Security Purchase Agreement was and $36,038 was added to the principal balance and charged to interest expense during the three and six months ended March 31, 2016. On August 13, 2015, the Company entered into an Amendment, Waiver and Modification Agreement (the “Amendment”) to its $2M Securities Purchase Agreement and related Transaction Documents with Redwood Management, LLC including any designees and or assignees thereto. Under the terms of the Amendment, the parties agreed to reduce the $2,000,000 outstanding balance of the $2M Note to $800,000 to reflect the total amount funded under the note, to terminate the offsetting investor note securing the additional unfunded balance and to waive any past claims of default or offsetting interest on the $2M Note or investor note. In addition, the conversion rate of the note was amended to 55% of the lowest price of the prior fifteen (15) trading days and conversion floor removed which amendment was triggered by the dilutive issuances of the August 2015 convertible note financing thereby entitling Investor to the lowest conversion rate granted during the year ended September 30, 2015 per the terms of the $2M Securities Purchase Agreement. As a result, we expensed the unamortized discount of $40,000 to loss on debt extinguishment. On August 13, 2015, the carrying value on the note was $655,816, net of unamortized discounts of $94,184. The Company recorded the note as a derivative liability at fair value of $970,956, a derivative discount of $655,816, and the excess in fair value of $315,140 to loss on debt extinguishment. The total loss on debt extinguishment on this note was $369,324. During the three and six months ended March 31, 2016, the Company amortized $47,405 and $472,628 of the derivative discount to interest expense, recorded a loss on the change in fair value of the derivative liability of $312,467 and $323,873, and allocated the fair value of $0 and $324,055 of the conversions below as additional paid-in-capital and a reduction in the derivative liability, respectively. As of March 31, 2016, the derivative liability was $419,321. The following is summary of conversions by the $2M Note holder (including its assignees) during the six months ended March 31, 2016: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 1, 2015 $ 10,000 $ - $ 10,000 $ 0.0148 675,676 October 5, 2015 10,000 - 10,000 $ 0.0148 675,676 October 6, 2015 13,262 - 13,262 $ 0.0138 961,000 October 7, 2015 10,000 - 10,000 $ 0.0115 865,801 October 9, 2015 11,728 - 11,728 $ 0.0116 1,011,000 October 9, 2015 10,000 - 10,000 $ 0.0115 865,801 October 12, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 13, 2015 11,601 - 11,601 $ 0.0116 1,000,052 October 15, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 19, 2015 17,400 - 17,400 $ 0.0116 1,500,000 October 19, 2015 15,000 - 15,000 $ 0.0116 1,298,701 October 20, 2015 16,650 - 16,650 $ 0.0111 1,500,000 October 21, 2015 17,500 - 17,500 $ 0.0115 1,515,152 October 23, 2015 20,000 - 20,000 $ 0.0115 1,731,602 October 26, 2015 24,420 - 24,420 $ 0.0111 2,200,000 October 29, 2015 26,640 - 26,640 $ 0.0111 2,400,000 November 2, 2015 29,970 - 29,970 $ 0.0111 2,700,000 November 2, 2015 20,000 - 20,000 $ 0.0111 1,809,136 November 5, 2015 32,190 - 32,190 $ 0.0111 2,900,000 November 10, 2015 28,800 - 28,800 $ 0.0096 3,000,000 November 12, 2015 23,930 - 23,930 $ 0.0072 3,323,611 November 17, 2015 16,500 - 16,500 $ 0.0060 2,727,273 November 19, 2015 1,640 11,225 12,865 $ 0.0056 2,316,013 November 23, 2015 23,111 - 23,111 $ 0.0056 4,127,000 November 27, 2015 24,750 - 24,750 $ 0.0055 4,500,000 December 2, 2015 18,450 - 18,450 $ 0.0041 4,500,000 December 8, 2015 18,000 - 18,000 $ 0.0036 5,000,000 December 11, 2015 13,368 - 13,368 $ 0.0024 5,570,000 December 16, 2015 14,181 - 14,181 $ 0.0024 5,860,000 December 22, 2015 15,488 - 15,488 $ 0.0024 6,400,000 December 29, 2015 17,666 17,666 $ 0.0024 7,300,000 $ 541,605 $ 11,225 $ 552,830 82,775,494 As a result, as of March 31, 2016, $91,024 is classified as current on the accompanying consolidated balance sheet. During the three and six months ended March 31, 2016 and 2015, the Company amortized $5,279 and $3,200, and $30,713 and $3,200 of the original issue discount to interest expense, respectively. As of March 31, 2016, there is $41,845 in accrued interest expense related to this note and the Company recorded $3,811 and $4,389, and $8,592 and $4,389 in interest expense during the three and six months ended March 31, 2016 and 2015, respectively. Convertible Note Financing On August 5, 2015, the Company entered into a series of convertible note financings with several accredited investors totaling an aggregate of $541,000 in aggregate proceeds raised less certain fees and costs as set forth in the financing documents known as the “August 2015 Notes”. The financing was disclosed on the Company’s Current Report on Form 8-K filed on August 11, 2015 and is incorporated herein by reference. The Company recorded an original issue discount of $12,500 along with these notes. On March 7, 2016, $112,000 of these notes were assigned to the same accredited investor previously mentioned and $7,806 was added to the principal balance and recorded as interest expense during the three and six months ended March 31, 2016. August 2015 Notes On August 5, 2015, the carrying value on the notes were $419,626, net of unamortized original issue discounts of $9,374. In six months when the note became convertible, the Company recorded the note as a derivative liability at fair value of $1,181,732, a derivative discount of $419,626, and the excess in fair value of $762,106 to excess of fair value of embedded conversion feature. The Company amortizes the derivative discount over the expected life of the related debt. During the three and six months ended March 31, 2016, the Company amortized $107,736 of the derivative discount to interest expense and recorded a loss on the change in fair value of the derivative liability of $396,268. As of March 31, 2016, the derivative liability was $1,578,000. During the three and six months ended March 31 2016, the Company amortized $1,563 and $3,126 of original issue discounts to interest expense. During the three and six months ended March 31 2016, the Company amortized $17,964 and $35,928 of debt issuance costs to interest expense. As of March 31, 2016, $83,773 is classified as current on the accompanying consolidated balance sheet, net of total unamortized discounts of $345,227. As of March 31, 2016, there is $29,434 in accrued interest expense related to these notes and the Company recorded $17,514 and $23,137 in interest expense during the three and six months ended March 31, 2016, respectively. Additional Funding Under August 2015 Note On December 15, 2015, an accredited investor provided the Company with $50,000 in additional proceeds under the same terms of their original convertible note with a term of two years. A one-time interest charge of $11,600 was added to the principal of the note. The Company also recorded $4,000 of debt issuance costs as a discount. During the three and six months ended March 31 2016, the Company amortized $500 debt issuance costs to interest expense. As a result, as of March 31, 2016, $58,100 is classified as current on the accompanying consolidated balance sheet, net of total unamortized discounts of $3,500. As of March 31, 2016, there is default interest of $1,848 in accrued interest expense related to these notes and the Company recorded $1,848 during the three and six months ended March 31, 2016, respectively. The Company will record an embedded conversion feature at estimated fair value as a derivative liability at fair value in six months if and when the notes become convertible. Assigned 2015 Notes On August 5, 2015, the carrying value on an assigned note was $112,000. In six months when the note became convertible, the Company recorded the note as a derivative liability at fair value of $400,722, a derivative discount of $112,000, and the excess in fair value of $288,722 to loss on debt extinguishment. During the three and six months ended March 31, 2016, the Company amortized $37,333 of the derivative discount to interest expense and recorded a loss on the change in fair value of the derivative liability of $293,003. As of March 31, 2016, the derivative liability was $693,725. During the three and six months ended March 31 2016, the Company amortized $3,429 and $8,571 of debt issuance costs to interest expense. Subsequent to quarter end, the Company enacted the following conversions: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued April 20, 2016 $ 16,117 $ - $ 16,117 $ 0.0024 6,660,000 April 25, 2016 46,349 - 46,349 $ 0.0029 15,900,000 May 5, 2016 37,744 - 37,744 $ 0.0025 15,250,000 May 18, 2016 19,597 1,594 21,191 $ 0.0020 10,413,268 $ 119,867 $ 1,594 $ 121,401 48,223,268 As a result, as of March 31, 2016, $45,140 is classified as long-term on the accompanying consolidated balance sheet, net of total unamortized discounts of $74,667. As of March 31, 2016, there is $10,937 in accrued interest expense related to these notes and the Company recorded $5,412 and $8,847 in interest expense during the three and six months ended March 31, 2016, respectively. On August 12, 2015, the Company entered into an additional convertible note financing transaction with an accredited investor in the principal amount of $105,000 less fees and costs. The same accredited investor was assigned mentioned above was assigned this note and $20,000 was added to the principal balance and recorded as interest expense during the three and six months ended March 31, 2016. The closing under the financing occurred concurrently with the execution of the financing documents on August 12, 2015. The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest. The maturity date of the convertible note is June 12, 2016 subject to the noteholder’s right to extend maturity an additional nine (9) month period. The Company recorded an original issue discount of $5,000 along with this note. In six months when the note became convertible, the Company recorded the note as a derivative liability at fair value of $110,669, a derivative discount of $103,000, and the excess in fair value of $7,669 to loss on debt extinguishment. During the three and six months ended March 31, 2016, the Company amortized $34,333 of the derivative discount to interest expense and recorded a loss on the change in fair value of the derivative liability of $275,424. As of March 31, 2016, the derivative liability was $386,093. During the three and six months ended March 31 2016, the Company amortized $1,500 and $3,000 of original issue discounts to interest expense. During the three and six months ended March 31 2016, the Company amortized $4,920 and $9,840 of debt issuance costs to interest expense. As a result, as of March 31, 2016, $52,053 is classified as current on the accompanying consolidated balance sheet, net of total unamortized discounts of $72,947. As of March 31, 2016, there is $8,597 in accrued interest expense related to these notes and the Company recorded $5,307 and $7,453 in interest expense during the three and six months ended March 31, 2016, respectively. The foregoing descriptions of the August 12, 2015 note financing and related documentation do not purport to be complete and are qualified in their entirety by reference to the full text of the documents, which are filed as exhibits to this Quarterly Report on Form 10-K/A and are incorporated herein by reference.

Related Party Debt

Related Party Debt	6 Months Ended
	Mar. 31, 2016
Related Party Debt [Abstract]
RELATED PARTY DEBT	NOTE 6. RELATED PARTY DEBT Related Party Note The Company had outstanding accounts payable balance to a related party (shareholder of the Company) in the amount of $15,000 as of September 30, 2013. This payable was converted into a note payable on December 7, 2013. The note payable bears interest of 6% per annum with a maturity date of December 1, 2016. As of March 31, 2016, there is $2,102 in accrued interest expense related to this note and the Company recorded $228 and $458 in interest expense related to this note during the three and six months ended March 31, 2016. Related Party Convertible Notes Payable On December 10, 2015, the Company entered into two Secured Series B Preferred Stock Convertible Notes (the “Series B Notes”) for an aggregate principal of $300,000 including 1) $50,000 from Hive Ceramics, LLC in new capital to the Company and 2) an amended and restated note for Hive Ceramics LLC in the amount of $250,000 for capital previously contributed which is soon to be due and payable. The Series B Notes accrue interest at eight percent (8%) per annum, mature one (1) year from issuance and are secured by all of the assets and property of the Company. Upon the election of the noteholder, the Series B Notes are convertible into newly created Series B Preferred Stock on a one-for-one (1:1) basis into shares of common stock of the Company at a fixed price per share of $0.01. Concurrently, the Company filed a Certificate of Designation with the Delaware Secretary of State on the Series B Preferred Stock which provides, in pertinent part, for the following rights and privileges: Authorized Amount of Series B Preferred Stock Voting Rights Rank pari passu During the three and six months ended March 31, 2016, the Company recorded $4,550 and $8,558 of interest expense related to the notes. As of December 31, 2015, $300,000 of the Series B Notes along with $31,452 of accrued interest are outstanding. The Board of Directors authorized the designation of the Series B Preferred Stock pursuant to the authority of the Certificate of Incorporation, which confers said authority on the Board, and the issuance of the Series B Notes pursuant to a unanimous written consent of the Board dated December 10, 2015. The value ascribed to the Series B Notes were based on the fixed conversion price of the instruments into common stock and such no beneficial conversion feature was recorded.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Office Lease As of March 31, 2016, the Company leases a 2,500 square foot office in Agoura Hills, California for approximately $2,500 per month which expires in December 2017. Warrant Liability The Company recorded the estimated settlement liability as of March 31, 2016 for the Warrant Shares issued and the Warrants that remain outstanding and unexercised that would be entitled to the same settlement based on the number of shares expected to be issued and the market price of the Company’s common stock on the dates of the actual settlements from $4.72 per share to $7.25 per share, and market price of the first settlement of $7.25 for the unsettled claims. We believe the issuance of convertible notes in the three months ended March 31, 2016 triggered the full ratchet anti-dilution adjustment; before the provision was triggered, the fair value of the warrant liability was not significant as the exercise was so far out of the money. As a result of the above settlements with warrant holders, the Company recorded a loss on settlement of warrants of $29,528,844 during the six months ended March 31, 2016 and a long-term warrant liability of $29,430,022 as of March 31, 2016 based on 4,407,200 shares of common stock under the settlement at the Company’s closing stock prices discussed above. As of March 31, 2016, the estimated settlement liability is $7,422 based on the fair market value of 1,184,727 remaining warrants and therefore the Company recorded a gain (loss) on the change in warrant liability of ($2,745) and $414,654, and $23,979 and 1,824,479 during the three and six months ended March 31, 2016 and 2015, respectively. Settlement of Company Legal Claims On December 15, 2014, the Company recorded a gain on settlement of $257,930 for a confidential settlement by and between the Company and certain shareholders and related parties as settlement for certain potential legal claims held by the Company. As a result of the settlement, the Company received net proceeds of $62,930 and vendor credits of $200,000 during the three months ended December 31, 2014. A total of $325,000 in vendor credits has been received in connection with the settlement and no further credits will be given. In January 2015, the Company received 440,625 shares from the settlement that was assigned to officers of the Company. The officers decided it was in the best interest of the Company to return these shares to the Company to be used for future strategic issuances. Accordingly, the 440,625 shares valued at $367,531 were recorded as treasury stock as of March 31, 2015. The Company recorded a gain on settlement of $0 and $367,531, and $0 and $625,461 during the three and six months ended March 31, 2016 and 2015, respectively.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Mar. 31, 2016
Stockholders' Deficit [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8. STOCKHOLDERS’ DEFICIT COMMON STOCK On November 27, 2013, the Board and shareholders approved an increase in the authorized number of shares of common and preferred stock which may be issued by the Company to 1,000,000,000 shares and 100,000,000 shares, respectively. On December 3, 2013, the certificate of amendment was filed with the Secretary of State of Delaware to reflect the increase in authorized. PREFERRED STOCK On April 1, 2014, the Board formally approved the filing of a Preferred Stock Designation in connection with the commitment of 500,000 Series A Shares to HIVE on March 27, 2014 pursuant to its authority to issue blank check preferred stock as provided in the Company’s Certificate of Incorporation. Per the Certificate of Designation (the “Designation”), there are 100,000,000 shares of preferred stock authorized by the Company’s Certificate of Incorporation. The Company is authorized to issue 500,000 shares of Series A Shares pursuant to the Designation. As provided in the Designation (and as set forth in the HIVE Asset Purchase Agreement), Series A Shares are entitled to vote at a 15-1 ratio to Common Stock. Each share of preferred stock shall initially be convertible into one share of common stock (500,000 shares of common stock in the aggregate). On the two year anniversary of the transaction of HIVE, the preferred stock conversion ratio shall be adjusted as follows: a one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company. On June 19, 2014, the Company formally issued the 500,000 Series A Shares to HIVE. The value ascribed to the Series A Shares was based on the historical costs of the assets acquired on March 27, 2014 from HIVE since the transfer of assets was made among entities under common control. On December 10, 2015, the Company approved the filing of a Preferred Stock Designation for up to 30,000,000 shares of Series B Preferred Stock. No Series B Preferred Stock are issued or outstanding. See discussion of designation of Series B Preferred Stock in Note 6. COMMON STOCK ISSUED FOR ACCRUED WAGES On October 22, 2015, the Company’s Board of Directors issued 2,083,333 shares of restricted common stock each to Kyle Tracey at $0.024 per share for payment of $50,000 in accrued wages. On October 22, 2015, the Company’s Board of Directors issued 555,555 shares of restricted common stock each to Kyle Tracey at $0.024 per share for payment of $13,333 in accrued wages. On October 22, 2015, the Company’s Board of Directors issued 1,250,000 shares of restricted common stock each to Michael Cook at $0.024 per share for payment of $3,000 in accrued wages. In February 2016, Justin Braune elected to take $15,000 of wages as common stock. The shares will formally be issued once the debt conversions and capital structure restrictions have been resolved. On March 31, 2016, the Company’s Board of Directors issued 250,000 shares of restricted common stock to Justin Braune at $0.01 per share for payment of $2,375 in accrued wages. To date, the Company has issued but not delivered 28,702,167 shares of common stock to Justin Braune in accrued wages. COMMON STOCK ISSUED FOR BONUSES On October 22, 2015, the Company’s Board of Directors issued bonus stock grants of 600,000 shares of restricted common stock each to Allan Viernes and Benjamin Beaulieu at $0.024 per share. In addition, the Company issued 300,000 shares of restricted common stock to employees at $0.024 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $36,000 being charged to general and administrative expense during the three months ended December 31, 2015. On October 22, 2015, the Company’s Board of Directors issued bonus stock grants of 1,250,000 shares of restricted common stock an outside sales consultant at $0.024 per share. The issuance was based on the fair market value on the date of issuance immediately vested and resulted in $30,000 being charged to sales and marketing expense during the three months ended December 31, 2015. COMMON STOCK ISSUED FOR SERVICES On November 25, 2015, the Company’s Board of Directors issued stock grants of 49,760 shares of restricted common stock a business development consultant at $0.011 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $547 being charged to general and administrative expense during the three months ended December 31, 2015. On December 23, 2015, the Company’s Board of Directors issued stock grants of 142,857 shares of restricted common stock a business development consultant at $0.008 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $1,143 being charged to general and administrative expense during the three months ended December 31, 2015. COMMON STOCK SURRENDERS On October 22, 2015, Joe Andreae surrendered 130,000 shares of restricted common stock valued at $3,120 and were recorded as treasury stock. In addition, on October 22, 2015, an employee also surrendered 30,000 shares valued at $360, which was recorded as treasury stock. On December 20, 2015, Kyle Tracey surrendered 130,000 shares of restricted common stock valued at $1,170 and were recorded as treasury stock. On December 21, 2015, the Allan Viernes and Benjamin Beaulieu each surrendered 30,000 shares of restricted common stock valued at $420, which was recorded as treasury stock. EQUITY INVESTMENT BY THE INVESTOR On December 10, 2015, the Investor purchased $90,000 in common stock at a purchase price equal to 90% of the average of the closing prices of the common stock for the three (3) trading days immediately preceding the date that is 6 months from the date of the agreement. As of December 31, 2015, proceeds of $90,000 have been recorded as common stock to be issued. WARRANTS The table below summarizes the Company’s warrant activity during the six month period ended March 31, 2016: Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at March 31, 2016 1,184,726 $ 0.003 0.1 $ 11,179 The Company’s warrants above are accounted for as derivative liabilities in the accompanying consolidated balance sheets.

Intellectual Property

Intellectual Property	6 Months Ended
	Mar. 31, 2016
Intellectual Property [Abstract]
INTELLECTUAL PROPERTY	NOTE 9. INTELLECTUAL PROPERTY The Company plans to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has begun to execute on this plan with the acquisition of the patent pending HIVE Ceramic vaporization product and the HIVE trademark as well as several pending trademark applications. The Company intends to continue to create or acquire proprietary vaporizers and e-cigarettes, and various trademarks, patents and/or copyrights for brands which are developed. TRADEMARKS On March 27, 2014, the Company and Stone Arch Studio, LLC entered into a Trademark Assignment Agreement whereby the Company acquired all right, title, priority and interest to the HIVE trademark U.S. Registration No. 44513069 as registered with the U.S. Patent and Trade Office (“USPTO”). This acquisition further protects the Company’s HIVE Ceramics brand vaporization line. In addition, the Company has filed for trademark protection with the USPTO on several additional trademarks and tradenames to be utilized by the Company in the future as the marks register. As of March 31, 2016, the Company has capitalized $123,150 in costs related to the trademarks. PATENTS On March 27, 2014, the Company formally closed its acquisition of the patent pending HIVE Ceramics vaporization technology. The Company has already begun exploiting this technology and intends to prosecute the patent application to completion. As of March 31, 2016, the Company has no patent costs capitalized. The Company is engaged in developing proprietary rights of the type that may be awarded patents for enhancements to its core HIVE product line as well as proprietary rights in related product lines. The Company also expects that from time to time it is in discussions to acquire additional patented technology from third parties to further grow and develop branded product lines in the vaporization market. See Note 1 regarding BetterChem unwind and rights to related patents.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10. SUBSEQUENT EVENTS See Note 5 regarding subsequent conversions.

Accounting Policies and Basis18

Accounting Policies and Basis of Presentation (Policies)	6 Months Ended
	Mar. 31, 2016
Accounting Policies and Basis of Presentation [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year.
CONSOLIDATION	CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Revival and Nouveau after elimination of all material inter-company accounts and transactions.
USE OF ESTIMATES	USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the convertible notes payable warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2016 and September 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at March 31, 2016: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 52,111 $ - $ - $ 52,111 Total assets measured at fair value $ 52,111 $ - $ - $ 52,111 Liabilities Derivative instruments $ - $ 3,796,083 $ - $ 3,796,083 Total liabilities measured at fair value $ - $ 3,796,083 $ - $ 3,796,083 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 1,704,127 $ - $ 1,704,127 Total liabilities measured at fair value $ - $ 1,704,127 $ - $ 1,704,127
CONCENTRATION	CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Three (3) customers accounted for 70% of our accounts receivable as of March 31, 2016. One (1) customer accounted for 37% of our accounts receivable as of September 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 73% and 74% of our purchases during the three and six months ended March 31, 2016. Two (2) suppliers and one (1) supplier accounted for 79% and 70% of our purchases during the three and six months ended March 31, 2015. The loss of these suppliers would have a significant impact on the Company’s financial results.
REVENUE RECOGNITION	REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is generally recorded when sales orders are shipped.
INVENTORY	INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired.
FIXED ASSETS	FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is two (2) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life of the asset.
IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS	IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three and six months ended March 31, 2016 and 2015, the Company did not record any impairment of its trademarks as its expected future cash flows are in excess of their carrying amounts.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and development costs include the research and development expenses related to prototypes of the Company’s products. During the three and months ended March 31, 2016 and 2015, research and development costs were $11,099 and $200, and $46,698 and $52,053, respectively.
CONVERTIBLE DEBT	CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. Many of the conversion features embedded in the Company's notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. In these cases, we record the embedded conversion feature as a derivate instrument, at fair value. The embedded conversion features are recorded as discounts when the notes become convertible. The excess of fair value of the embedded conversion feature over the carrying value of the debt is recorded as an immediate charge to operations. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt using the effective interest method. The Company has lost the ability to increase the share reserves due to the significantly increased outstanding held by convertible noteholders and a shareholder vote is required to increase the authorized amount of shares the Company may issue. Further, the combination of limited capital and depleted share reserves have severely damaged the Company’s ability to find continued finance, properly run the Company, and proceed with business to include any mergers or acquisitions or any transactions that would require available stock.
DERIVATIVE FINANCIAL INSTRUMENTS	DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes.
EARNINGS (LOSS) PER COMMON SHARE	EARNINGS (LOSS) PER COMMON SHARE Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. In the event of losses, such common share equivalents are excluded as their effects are antidilutive. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three and six months ended March 31, 2016: For the Three Months Ended For the Six Months Ended March 31, March 31, 2016 2016 Series A Preferred stock 500,000 500,000 Common stock warrants 1,184,726 1,184,726 Convertible notes 631,560,394 631,560,394 633,245,120 633,245,120 The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders: For the Three Months For the Six Months March 31, March 31, Weighted average common shares outstanding used in calculating basic earnings per share 11,148,666 10,918,103 Effect of preferred stock 500,000 500,000 Effect of convertible notes payable 2,025,679 2,025,679 Effect of options and warrants 197,143 161,264 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,871,488 13,605,046 Net income as reported $ 85,145 $ 668,055 Add - interest on convertible notes payable 100,075 323,506 Net income available to common stockholders $ 185,220 $ 991,561 The Company excluded 751,250 and 502,500 options from the computation for the three and six months ended March 31, 2015, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the six months ended March 31, 2016 and 2015: Six Months Ended March, Stock Price at Grant Date Dividend Yield Exercise Price Risk Free Interest Rate Volatility Average Life 2016 n/a n/a n/a n/a n/a n/a 2015 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Prepaid stock-based compensation is recorded when shares are issued based on the value on the grant date, but vest over the contractual period at which time the prorated expense will be recorded.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In April 2015, the FASB issued Accounting Standard Update ("ASU") 2015-03 Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be classified as a reduction to the carrying value of debt rather than a deferred charge, as is currently required. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented, and early adoption is permitted. The Company adopted the policy during the quarter ending March 31, 2016. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.
RISKS AND UNCERTAINTIES	RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Accounting Policies and Basis19

Accounting Policies and Basis of Presentation (Tables)	6 Months Ended
	Mar. 31, 2016
Accounting Policies and Basis of Presentation [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 52,111 $ - $ - $ 52,111 Total assets measured at fair value $ 52,111 $ - $ - $ 52,111 Liabilities Derivative instruments $ - $ 3,796,083 $ - $ 3,796,083 Total liabilities measured at fair value $ - $ 3,796,083 $ - $ 3,796,083 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 1,704,127 $ - $ 1,704,127 Total liabilities measured at fair value $ - $ 1,704,127 $ - $ 1,704,127
Schedule of securities to be included in diluted share calculation	For the Three Months Ended For the Six Months Ended March 31, March 31, 2016 2016 Series A Preferred stock 500,000 500,000 Common stock warrants 1,184,726 1,184,726 Convertible notes 631,560,394 631,560,394 633,245,120 633,245,120
Schedule of reconcilliation of net income available to common shareholders	For the Three Months For the Six Months March 31, March 31, Weighted average common shares outstanding used in calculating basic earnings per share 11,148,666 10,918,103 Effect of preferred stock 500,000 500,000 Effect of convertible notes payable 2,025,679 2,025,679 Effect of options and warrants 197,143 161,264 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,871,488 13,605,046 Net income as reported $ 85,145 $ 668,055 Add - interest on convertible notes payable 100,075 323,506 Net income available to common stockholders $ 185,220 $ 991,561
Schedule of weighted average variables used in Black Scholes model	Six Months Ended March, Stock Price at Grant Date Dividend Yield Exercise Price Risk Free Interest Rate Volatility Average Life 2016 n/a n/a n/a n/a n/a n/a 2015 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0

Fixed Assets (Tables)

Fixed Assets (Tables)	6 Months Ended
	Mar. 31, 2016
Fixed Assets [Abstract]
Summary of fixed assets	March 31, September 30, Molds and Tooling $ 218,490 $ 176,015 Leasehold improvements - 29,795 Accumulated depreciation (134,221 ) (87,483 ) $ 84,269 $ 118,327

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Mar. 31, 2016
Accrued Expenses [Abstract]
Summary of accrued expenses	March 31, September 30, Accrued interest $ 120,529 $ 46,337 Accrued interest - related party 33,554 24,538 Accrued wages and taxes 121,122 112,322 Other 14,373 24,411 $ 289,578 $ 207,608

Third Party Debt (Tables)

Third Party Debt (Tables)	6 Months Ended
	Mar. 31, 2016
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Shedule of conversions for payments	Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 8, 2015 $ 21,000 $ - $ 21,000 $ 0.012 1,818,182 October 16, 2015 18,900 - 18,900 $ 0.012 1,636,364 October 22, 2015 25,800 - 25,800 $ 0.011 2,333,786 October 29, 2015 22,460 - 22,460 $ 0.011 2,031,660 November 11, 2015 33,500 - 33,500 $ 0.007 4,649,549 November 18, 2015 24,000 - 24,000 $ 0.006 4,195,804 November 30, 2015 30,000 - 30,000 $ 0.005 5,741,627 December 11, 2015 22,000 - 22,000 $ 0.002 9,090,909 December 28, 2015 22,500 - 22,500 $ 0.002 9,297,521 January 7, 2016 20,000 - 20,000 $ 0.002 10,101,010 January 20, 2016 12,500 - 12,500 $ 0.001 10,330,579 February 2, 2016 13,200 - 13,200 $ 0.001 10,909,091 March 2, 2016 10,627 - 10,627 $ 0.001 10,169,800 March 10, 2016 11,184 - 11,184 $ 0.001 10,702,619 March 17, 2016 8,272 - 8,272 $ 0.001 6,539,200 March 29, 2016 22,797 - 22,797 $ 0.002 12,191,000 March 31, 2016 22,347 - 22,347 $ 0.002 11,950,000 $ 341,087 $ - $ 341,087 123,688,701 Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued April 4, 2016 $ 25,140 $ - $ 25,140 $ 0.002 13,444,000 April 7, 2016 21,019 - 21,019 $ 0.002 11,240,000 April 13, 2016 35,664 - 35,664 $ 0.002 14,737,000 April 19, 2016 36,711 - 36,711 $ 0.002 15,170,000 April 20, 2016 18,244 - 18,244 $ 0.002 7,538,666 $ 136,778 $ - $ 136,778 62,129,666
$2M Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Shedule of conversions for payments	Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 1, 2015 $ 10,000 $ - $ 10,000 $ 0.0148 675,676 October 5, 2015 10,000 - 10,000 $ 0.0148 675,676 October 6, 2015 13,262 - 13,262 $ 0.0138 961,000 October 7, 2015 10,000 - 10,000 $ 0.0115 865,801 October 9, 2015 11,728 - 11,728 $ 0.0116 1,011,000 October 9, 2015 10,000 - 10,000 $ 0.0115 865,801 October 12, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 13, 2015 11,601 - 11,601 $ 0.0116 1,000,052 October 15, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 19, 2015 17,400 - 17,400 $ 0.0116 1,500,000 October 19, 2015 15,000 - 15,000 $ 0.0116 1,298,701 October 20, 2015 16,650 - 16,650 $ 0.0111 1,500,000 October 21, 2015 17,500 - 17,500 $ 0.0115 1,515,152 October 23, 2015 20,000 - 20,000 $ 0.0115 1,731,602 October 26, 2015 24,420 - 24,420 $ 0.0111 2,200,000 October 29, 2015 26,640 - 26,640 $ 0.0111 2,400,000 November 2, 2015 29,970 - 29,970 $ 0.0111 2,700,000 November 2, 2015 20,000 - 20,000 $ 0.0111 1,809,136 November 5, 2015 32,190 - 32,190 $ 0.0111 2,900,000 November 10, 2015 28,800 - 28,800 $ 0.0096 3,000,000 November 12, 2015 23,930 - 23,930 $ 0.0072 3,323,611 November 17, 2015 16,500 - 16,500 $ 0.0060 2,727,273 November 19, 2015 1,640 11,225 12,865 $ 0.0056 2,316,013 November 23, 2015 23,111 - 23,111 $ 0.0056 4,127,000 November 27, 2015 24,750 - 24,750 $ 0.0055 4,500,000 December 2, 2015 18,450 - 18,450 $ 0.0041 4,500,000 December 8, 2015 18,000 - 18,000 $ 0.0036 5,000,000 December 11, 2015 13,368 - 13,368 $ 0.0024 5,570,000 December 16, 2015 14,181 - 14,181 $ 0.0024 5,860,000 December 22, 2015 15,488 - 15,488 $ 0.0024 6,400,000 December 29, 2015 17,666 17,666 $ 0.0024 7,300,000 $ 541,605 $ 11,225 $ 552,830 82,775,494 Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued April 20, 2016 $ 16,117 $ - $ 16,117 $ 0.0024 6,660,000 April 25, 2016 46,349 - 46,349 $ 0.0029 15,900,000 May 5, 2016 37,744 - 37,744 $ 0.0025 15,250,000 May 18, 2016 19,597 1,594 21,191 $ 0.0020 10,413,268 $ 119,867 $ 1,594 $ 121,401 48,223,268

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Mar. 31, 2016
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of company's warrant activity	Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at March 31, 2016 1,184,726 $ 0.003 0.1 $ 11,179

Description of Business and S24

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)	Jan. 12, 2016	Dec. 10, 2015	Oct. 22, 2015	Jul. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Description of Business and Summary of Significant Accounting Policies (Textuals)
Cash					$ 52,111	$ 241,691	$ 52,111	$ 241,691	$ 273,904	$ 48,370
Net income (loss)					(3,956,043)	$ 85,145	(5,300,461)	$ 668,055
Accumulated deficit					(33,467,206)		(33,467,206)		$ (28,166,745)
Restricted common stock issued, Shares			600,000
Common stock to be issued		$ 90,000					90,000
Working capital deficit					$ 4,574,844		$ 4,574,844
Affiliated Entity [Member]
Description of Business and Summary of Significant Accounting Policies (Textuals)
Description of acquired entity				In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem.
Common stock to be issued, Shares				250,000
Common stock to be issued				$ 67,500
Impairment charges	$ 69,250
Affiliated Entity [Member] | Dr. Mark Scialdone [Member]
Description of Business and Summary of Significant Accounting Policies (Textuals)
Acquired controlling interest percentage				80.00%
Restricted common stock issued, Shares				400,000

Accounting Policies and Basis25

Accounting Policies and Basis of Presentation (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Assets
Cash and cash equivalents	$ 52,111	$ 273,904
Total assets measured at fair value	52,111	273,904
Liabilities
Derivative instruments	3,796,083	1,704,127
Total liabilities measured at fair value	3,796,083	1,704,127
Level 1 [Member]
Assets
Cash and cash equivalents	52,111	273,904
Total assets measured at fair value	$ 52,111	$ 273,904
Liabilities
Derivative instruments
Total liabilities measured at fair value
Level 2 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments	$ 3,796,083	$ 1,704,127
Total liabilities measured at fair value	$ 3,796,083	$ 1,704,127
Level 3 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments
Total liabilities measured at fair value

Accounting Policies and Basis26

Accounting Policies and Basis of Presentation (Details 1) - shares	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2016
Diluted shares outstanding	633,245,120	633,245,120
Series A Preferred stock [Member]
Diluted shares outstanding	500,000	500,000
Common stock warrants [Member]
Diluted shares outstanding	1,184,726	1,184,726
Convertible notes [Member]
Diluted shares outstanding	631,560,394	631,560,394

Accounting Policies and Basis27

Accounting Policies and Basis of Presentation (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies and Basis of Presentation [Abstract]
Weighted average common shares outstanding used in calculating basic earnings per share		11,148,666		10,918,103
Effect of preferred stock		500,000		500,000
Effect of convertible notes payable		2,025,679		2,025,679
Effect of options and warrants		197,143		161,264
Weighted average common and common equivalent shares used in calculating diluted earnings per share	116,275,351	13,871,488	148,949,185	13,605,046
Net income as reported	$ (3,956,043)	$ 85,145	$ (5,300,461)	$ 668,055
Add - interest on convertible notes payable		100,075		323,506
Net income available to common stockholders		$ 185,220		$ 991,561

Accounting Policies and Basis28

Accounting Policies and Basis of Presentation (Details 3) - $ / shares	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Weighted average variables used in the Black Scholes model
Stock Price at Grant Date		$ 0.73
Dividend Yield
Exercise Price		$ 0.73
Risk Free Interest Rate		2.20%
Volatility		380.00%
Average Life		10 years

Accounting Policies and Basis29

Accounting Policies and Basis of Presentation (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2016USD ($)suppliers	Mar. 31, 2015USD ($)suppliersshares	Mar. 31, 2016USD ($)customersuppliers	Mar. 31, 2015USD ($)suppliersshares	Sep. 30, 2015customer
Accounting policies and basis of presentation (Textual)
Inventory related text			We purchase product sourced from China which we are required to pay 50% upon placing the order.
Estimated useful lives			2 years
Research and development expense | $	$ 11,099	$ 200	$ 46,698	$ 52,053
Number of options excluded from the compution of diluted shares outstanding | shares		751,250		502,500
Customer [Member]
Accounting policies and basis of presentation (Textual)
Number of customers | customer			3		1
Credit risk rate			70.00%		37.00%
Suppliers [Member]
Accounting policies and basis of presentation (Textual)
Number of suppliers | suppliers	2	2	2	1
Credit risk rate	73.00%	79.00%	74.00%	70.00%

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Fixed Assets [Abstract]
Molds and Tooling	$ 218,490	$ 176,015
Leasehold improvements		29,795
Accumulated depreciation	$ (134,221)	(87,483)
Fixed assets, net	$ 84,269	$ 118,327

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fixed Assets [Abstract]
Depreciation expense	$ 76,533	$ 29,815

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Summary of Accrued Expenses:
Accrued interest	$ 120,529	$ 46,337
Accrued interest - related party	33,554	24,538
Accrued wages and taxes	121,122	112,322
Other	14,373	24,411
Accrued expenses	$ 289,578	$ 207,609

Accrued Expenses (Details Textu

Accrued Expenses (Details Textuals) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Accrued Expenses (Textual)
Accrued Wages And Taxes	$ 121,122	$ 112,322
Justin Brauneare [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	10,807
Joe Andreae [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	16,667
Mike Cook [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	33,742
Allan Viernes [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	11,055
Benjamin Beaulieu [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	11,055
Kyle Tracey
Accrued Expenses (Textual)
Accrued Wages And Taxes	$ 25,000

Third Party Debt (Details)

Third Party Debt (Details) - USD ($)	Dec. 14, 2015	Dec. 10, 2015	Mar. 12, 2015	Mar. 31, 2016	Aug. 12, 2015	Dec. 03, 2014
Debt Instrument [Line Items]
Principal Converted					$ 105,000
Total Converted	$ 30,000		$ 80,000
Common Shares Issued		90,000
Securities purchase agreement [Member]
Debt Instrument [Line Items]
Principal Converted				$ 341,087		$ 500,000
Total Converted				$ 341,087
Common Shares Issued				123,688,701
Accrued Interest Converted
Securities purchase agreement [Member] | October 8, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 21,000
Total Converted				$ 21,000
Common Shares Issued				1,818,182
Accrued Interest Converted
Conversion Rate				$ 0.012
Securities purchase agreement [Member] | October 16, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 18,900
Total Converted				$ 18,900
Common Shares Issued				1,636,364
Accrued Interest Converted
Conversion Rate				$ 0.012
Securities purchase agreement [Member] | October 22, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 25,800
Total Converted				$ 25,800
Common Shares Issued				2,333,786
Accrued Interest Converted
Conversion Rate				$ 0.011
Securities purchase agreement [Member] | October 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 22,460
Total Converted				$ 22,460
Common Shares Issued				2,031,660
Accrued Interest Converted
Conversion Rate				$ 0.011
Securities purchase agreement [Member] | November 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 33,500
Total Converted				$ 33,500
Common Shares Issued				4,649,549
Accrued Interest Converted
Conversion Rate				$ 0.007
Securities purchase agreement [Member] | November 18, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 24,000
Total Converted				$ 24,000
Common Shares Issued				4,195,804
Accrued Interest Converted
Conversion Rate				$ 0.006
Securities purchase agreement [Member] | November 30, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 30,000
Total Converted				$ 30,000
Common Shares Issued				5,741,627
Accrued Interest Converted
Conversion Rate				$ 0.005
Securities purchase agreement [Member] | December 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 22,000
Total Converted				$ 22,000
Common Shares Issued				9,090,909
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities purchase agreement [Member] | December 28, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 22,500
Total Converted				$ 22,500
Common Shares Issued				9,297,521
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities purchase agreement [Member] | January 7, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 20,000
Total Converted				$ 20,000
Common Shares Issued				10,101,010
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities purchase agreement [Member] | January 20, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 12,500
Total Converted				$ 12,500
Common Shares Issued				10,330,579
Accrued Interest Converted
Conversion Rate				$ 0.001
Securities purchase agreement [Member] | February 2, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 13,200
Total Converted				$ 13,200
Common Shares Issued				10,909,091
Accrued Interest Converted
Conversion Rate				$ 0.001
Securities purchase agreement [Member] | March 2, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 10,627
Total Converted				$ 10,627
Common Shares Issued				10,169,800
Accrued Interest Converted
Conversion Rate				$ 0.001
Securities purchase agreement [Member] | March 10, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 11,184
Total Converted				$ 11,184
Common Shares Issued				10,702,619
Accrued Interest Converted
Conversion Rate				$ 0.001
Securities purchase agreement [Member] | March 17, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 8,272
Total Converted				$ 8,272
Common Shares Issued				6,539,200
Accrued Interest Converted
Conversion Rate				$ 0.001
Securities purchase agreement [Member] | March 29, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 22,797
Total Converted				$ 22,797
Common Shares Issued				12,191,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities purchase agreement [Member] | March 31, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 22,347
Total Converted				$ 22,347
Common Shares Issued				11,950,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities Purchase Agreement Two [Member]
Debt Instrument [Line Items]
Principal Converted				$ 136,778
Total Converted				$ 136,778
Common Shares Issued				62,129,666
Accrued Interest Converted
Securities Purchase Agreement Two [Member] | April 4, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 25,140
Total Converted				$ 25,140
Common Shares Issued				13,444,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities Purchase Agreement Two [Member] | April 7, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 21,019
Total Converted				$ 21,019
Common Shares Issued				11,240,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities Purchase Agreement Two [Member] | April 13, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 35,664
Total Converted				$ 35,664
Common Shares Issued				14,737,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities Purchase Agreement Two [Member] | April 19, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 36,711
Total Converted				$ 36,711
Common Shares Issued				15,170,000
Accrued Interest Converted
Conversion Rate				$ 0.002
Securities Purchase Agreement Two [Member] | April 20, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 18,244
Total Converted				$ 18,244
Common Shares Issued				7,538,666
Accrued Interest Converted
Conversion Rate				$ 0.002

Third Party Debt (Details 1)

Third Party Debt (Details 1) - USD ($)	Dec. 14, 2015	Dec. 10, 2015	Mar. 12, 2015	Mar. 31, 2016	Aug. 13, 2015	Aug. 12, 2015
Debt Instrument [Line Items]
Principal Converted						$ 105,000
Total Converted	$ 30,000		$ 80,000
Converted shares issued		90,000
$2M Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal Converted				$ 541,605	$ 2,000,000
Total Converted				$ 552,830
Converted shares issued				82,775,494
Accrued interest converted				$ 11,225
$2M Securities Purchase Agreement [Member] | October 1, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				10,000
Total Converted				$ 10,000
Converted shares issued				675,676
Accrued interest converted
Conversion Rate				$ 0.0148
$2M Securities Purchase Agreement [Member] | October 5, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 10,000
Total Converted				$ 10,000
Converted shares issued				675,676
Accrued interest converted
Conversion Rate				$ 0.0148
$2M Securities Purchase Agreement [Member] | October 6, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 13,262
Total Converted				$ 13,262
Converted shares issued				961,000
Accrued interest converted
Conversion Rate				$ 0.0138
$2M Securities Purchase Agreement [Member] | October 7, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 10,000
Total Converted				$ 10,000
Converted shares issued				865,801
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 9, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 11,728
Total Converted				$ 11,728
Converted shares issued				1,011,000
Accrued interest converted
Conversion Rate				$ 0.0116
$2M Securities Purchase Agreement [Member] | October 9, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 10,000
Total Converted				$ 10,000
Converted shares issued				865,801
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 12, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 14,680
Total Converted				$ 14,680
Converted shares issued				1,271,000
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 13, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 11,601
Total Converted				$ 11,601
Converted shares issued				1,000,052
Accrued interest converted
Conversion Rate				$ 0.0116
$2M Securities Purchase Agreement [Member] | October 15, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 14,680
Total Converted				$ 14,680
Converted shares issued				1,271,000
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 17,400
Total Converted				$ 17,400
Converted shares issued				1,500,000
Accrued interest converted
Conversion Rate				$ 0.0116
$2M Securities Purchase Agreement [Member] | October 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 15,000
Total Converted				$ 15,000
Converted shares issued				1,298,701
Accrued interest converted
Conversion Rate				$ 0.0116
$2M Securities Purchase Agreement [Member] | October 20, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 16,650
Total Converted				$ 16,650
Converted shares issued				1,500,000
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | October 21, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 17,500
Total Converted				$ 17,500
Converted shares issued				1,515,152
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 23, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 20,000
Total Converted				$ 20,000
Converted shares issued				1,731,602
Accrued interest converted
Conversion Rate				$ 0.0115
$2M Securities Purchase Agreement [Member] | October 26, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 24,420
Total Converted				$ 24,420
Converted shares issued				2,200,000
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | October 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 26,640
Total Converted				$ 26,640
Converted shares issued				2,400,000
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | November 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 29,970
Total Converted				$ 29,970
Converted shares issued				2,700,000
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | November 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 20,000
Total Converted				$ 20,000
Converted shares issued				1,809,136
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | November 5, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 32,190
Total Converted				$ 32,190
Converted shares issued				2,900,000
Accrued interest converted
Conversion Rate				$ 0.0111
$2M Securities Purchase Agreement [Member] | November 10, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 28,800
Total Converted				$ 28,800
Converted shares issued				3,000,000
Accrued interest converted
Conversion Rate				$ 0.0096
$2M Securities Purchase Agreement [Member] | November 12, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 23,930
Total Converted				$ 23,930
Converted shares issued				3,323,611
Accrued interest converted
Conversion Rate				$ 0.0072
$2M Securities Purchase Agreement [Member] | November 17, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 16,500
Total Converted				$ 16,500
Converted shares issued				2,727,273
Accrued interest converted
Conversion Rate				$ 0.0060
$2M Securities Purchase Agreement [Member] | November 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 1,640
Total Converted				$ 12,865
Converted shares issued				2,316,013
Accrued interest converted				$ 11,225
Conversion Rate				$ 0.0056
$2M Securities Purchase Agreement [Member] | November 23, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 23,111
Total Converted				$ 23,111
Converted shares issued				4,127,000
Accrued interest converted
Conversion Rate				$ 0.0056
$2M Securities Purchase Agreement [Member] | November 27, 2015 [member]
Debt Instrument [Line Items]
Principal Converted				$ 24,750
Total Converted				$ 24,750
Converted shares issued				4,500,000
Accrued interest converted
Conversion Rate				$ 0.0055
$2M Securities Purchase Agreement [Member] | December 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 18,450
Total Converted				$ 18,450
Converted shares issued				4,500,000
Accrued interest converted
Conversion Rate				$ 0.0041
$2M Securities Purchase Agreement [Member] | December 8, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 18,000
Total Converted				$ 18,000
Converted shares issued				5,000,000
Accrued interest converted
Conversion Rate				$ 0.0036
$2M Securities Purchase Agreement [Member] | December 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 13,368
Total Converted				$ 13,368
Converted shares issued				5,570,000
Accrued interest converted
Conversion Rate				$ 0.0024
$2M Securities Purchase Agreement [Member] | December 16, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 14,181
Total Converted				$ 14,181
Converted shares issued				5,860,000
Accrued interest converted
Conversion Rate				$ 0.0024
$2M Securities Purchase Agreement [Member] | December 22, 2015 [member]
Debt Instrument [Line Items]
Principal Converted				$ 15,488
Total Converted				$ 15,488
Converted shares issued				6,400,000
Accrued interest converted
Conversion Rate				$ 0.0024
$2M Securities Purchase Agreement [Member] | December 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 17,666
Total Converted				$ 17,666
Converted shares issued				7,300,000
Accrued interest converted
Conversion Rate				$ 0.0024
$2M Securities Purchase Agreement [Member] | April 20, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 16,117
Total Converted				$ 16,117
Converted shares issued				6,660,000
Accrued interest converted
Conversion Rate				$ 0.0024
$2M Securities Purchase Agreement [Member] | April 25, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 46,349
Total Converted				$ 46,349
Converted shares issued				15,900,000
Accrued interest converted
Conversion Rate				$ 0.0029
$2M Securities Purchase Agreement [Member] | May 5, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 37,744
Total Converted				$ 37,744
Converted shares issued				15,250,000
Accrued interest converted
Conversion Rate				$ 0.0025
$2M Securities Purchase Agreement [Member] | May 18, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted				$ 19,597
Total Converted				$ 21,191
Converted shares issued				10,413,268
Accrued interest converted				$ 1,594
Conversion Rate				$ 0.0020
$2M Securities Purchase Agreement One [Member]
Debt Instrument [Line Items]
Principal Converted				$ 119,867
Total Converted				$ 121,401
Converted shares issued				48,223,268
Accrued interest converted				$ 1,594

Third Party Debt (Details Textu

Third Party Debt (Details Textual) - USD ($)	Dec. 15, 2015	Aug. 13, 2015	Aug. 12, 2015	Dec. 03, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Debt Instrument [Line Items]
Original issue discount					$ 5,000			$ 5,000
Aggregate principal amount			$ 105,000
Proceeds from Issuance of Debt
Interest expense related to notes payable					4,550			$ 8,558
Amortized discount to interest expense					7,656		$ 7,656	15,312	$ 10,209
Convertible notes payable, long-term					26,541			26,541		$ 300,156
Unamortized discount convertible notes payable, current					87,121			87,121		153,096
Unamortized discount convertible notes payable, non current					19,159			19,159		655,607
Maturity date			Jun. 12, 2016
Accrued interest					29,434			29,434
Interest Expense	$ 11,600				540,942		93,488	1,318,885	171,478	8,596
Fair value of derivative liability					110,669			110,669
Derivative discount					$ 249,500			$ 103,000
Loss on debt extinguishment		$ 369,324					(19,981)		(19,981)
Derivative Liability, Current					$ 3,788,661			$ 3,788,661		1,672,726
Convertible notes payable, current					298,181			298,181		522,396
Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible notes payable, long-term					102,379			102,379
Unamortized discount convertible notes payable, current					4,445			4,445
Unamortized discount convertible notes payable, non current					34,399			34,399
Accrued interest					27,869			27,869
Interest Expense					9,328		14,000	17,924	18,356
Convertible Note Financing [Member]
Debt Instrument [Line Items]
Transaction expenses					4,920			9,840
Aggregate principal amount			$ 105,000
Maturity date			Jun. 12, 2016
Accrued interest					8,597			8,597
Interest Expense					20,000			20,000
Total unamortized discounts					72,947			72,947
Conversion description			The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest.
Derivative Liability, Current					386,093			386,093
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Unsecured convertible promissory note principal amount				$ 560,000
Original issue discount				50,000
Transaction expenses				10,000				45,940
Aggregate principal amount				500,000	341,087			341,087
Finder's fee				25,000
Proceeds from Issuance of Debt				$ 475,000
Interest expense related to notes payable					21,874	$ 105,000		21,874
Amortized discount to interest expense					8,333		8,333	16,667	11,111
Unamortized current					584			584
Long term debt issuance costs					4,521			4,521
Fair value of derivative liability					0			0
Loss on debt extinguishment								158,916
$2M Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount		2,000,000			541,605			541,605
Proceeds from Issuance of Debt										$ 651,395
Amortized discount to interest expense					47,405			472,628
Unamortized discount convertible notes payable, current					25,445			25,445
Interest Expense								4,781
Loss on debt in unamortized discount					40,000			40,000
Value of note issued		655,816
Unamortized discount		94,184
Fair value of derivative liability		970,956			419,321			419,321
Derivative discount		655,816
Loss on debt extinguishment		$ 315,140
$2M Securities Purchase Agreement [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Amortized discount to interest expense					5,279		3,200	30,713	3,200
Accrued interest					41,845			41,845
Interest Expense					$ 3,811		$ 4,389	$ 8,592	$ 4,389

Related Party Debt (Details)

Related Party Debt (Details) - USD ($)	Dec. 10, 2015	Aug. 12, 2015	Dec. 07, 2013	Mar. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Mar. 12, 2015	Nov. 27, 2013	Sep. 30, 2013
Related Party Debt (Textual)
Accrued interest				$ 120,529	$ 120,529		$ 46,337
Interest expense related to notes payable				$ 4,550	$ 8,558
Interest rate								6.00%
Maturity date		Jun. 12, 2016
Preferred stock, shares authorized				100,000,000	100,000,000		100,000,000		100,000,000
Shareholder [Member]
Related Party Debt (Textual)
Accounts payable, related parties										$ 15,000
Accrued interest				$ 2,102	$ 2,102
Interest expense related to notes payable				$ 228	$ 458
Interest rate			6.00%
Maturity date			Dec. 1, 2016
Series B Preferred Stock [Member]
Related Party Debt (Textual)
Accrued interest						$ 31,452
Interest rate	8.00%
Term of convertible note	1 year
Common stock conversion basis	Series B Preferred Stock on a one-for-one (1:1) basis into shares of common stock of the Company at a fixed price per share of $0.01.
Common stock fixed price per share	$ 0.01
Preferred stock, shares authorized	30,000,000
Voting rights, description	Each share of Series B shall be entitled to five (5) votes for every one (1) vote entitled to each share of Common Stock.
Aggregate principal amount	$ 300,000					$ 300,000
Equity investment by the investor, description	1) $50,000 from Hive Ceramics, LLC in new capital to the Company and 2) an amended and restated note for Hive Ceramics LLC in the amount of $250,000 for capital previously contributed which is soon to be due and payable.

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 15, 2014USD ($)	Jan. 31, 2015shares	Mar. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)ft²	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)	Oct. 22, 2015$ / shares	Sep. 30, 2015USD ($)shares
Commitments and Contingencies (Textual)
Leases rent expense				$ 2,500
Company leases for office | ft²				2,500
Lease expiration date				Dec. 31, 2017
Shares issued, price per share | $ / shares									$ 0.024
Warrant liability			$ 7,422				$ 7,422			$ 31,401
Gain on change in warrant liability			$ (2,745)		$ 414,654		$ 23,979	$ 1,824,479
Gain on settlement				$ 0	$ 367,531	$ 257,930		625,461
Proceeds from legal settlements						62,930		$ 62,930
Vendor credits on settlement						200,000
Total vendor credits on settlement						$ 325,000
Treasury stock, shares | shares			1,025,625				1,025,625			690,625
Treasury stock, value			$ 372,601				$ 372,601			$ 367,531
Officer [Member]
Commitments and Contingencies (Textual)
Shares assigned to officers | shares		440,625
Treasury stock, shares | shares			440,625				440,625
Treasury stock, value			$ 367,531				$ 367,531
Shareholders and Related Parties [Member]
Commitments and Contingencies (Textual)
Gain on settlement	$ 257,930
Warrants [Member]
Commitments and Contingencies (Textual)
Shares issued, price per share | $ / shares			$ 7.25				$ 7.25
Loss on settlement of warrants							$ 29,528,844
Long term warrant liability			$ 29,430,022				$ 29,430,022
Closing stock shares | shares			4,407,200				4,407,200
Warrant liability			$ 7,422				$ 7,422
Fair value of warrant liability			$ 1,184,727				$ 1,184,727
Warrants [Member] | Minimum [Member]
Commitments and Contingencies (Textual)
Shares issued, price per share | $ / shares			$ 4.72				$ 4.72
Warrants [Member] | Maximum [Member]
Commitments and Contingencies (Textual)
Shares issued, price per share | $ / shares			$ 7.25				$ 7.25

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Warrant [Member]	6 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
WARRANTS
Warrants outstanding, Shares, Beginning balance | shares	1,184,726
Warrants issued | shares
Warrants exercised | shares
Warrants cancelled/forfeited/expired | shares
Warrants outstanding, Shares, Ending Balance | shares	1,184,726
Warrants Weighted Average Price, Beginning balance | $ / shares	$ 0.114
Warrants issued, Weighted Average Price | $ / shares
Warrants exercised, Weighted Exercise Price | $ / shares
Warrants Cancelled/forfeited/expired, Weighted Average Price | $ / shares
Warrants Weighted Average Price, Ending Balance | $ / shares	$ 0.003
Warrants outstanding, Weighted Average Remaining Contractual Term, Beginning	10 months 24 days
Warrants outstanding, Weighted Average Remaining Contractual Term, Ending	1 month 6 days
Warrants Outstanding, Aggregate Intrinsic Value, Beginning balance | $	$ 739,812
Warrants Outstanding, Aggregate Intrinsic value, Ending Balance | $	$ 11,179

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - USD ($)

Dec. 10, 2015

Dec. 10, 2015

Apr. 01, 2014

Dec. 23, 2015

Dec. 21, 2015

Dec. 20, 2015

Nov. 25, 2015

Oct. 22, 2015

Jun. 19, 2014

Dec. 31, 2015

Mar. 31, 2016

Mar. 31, 2015

Sep. 30, 2015

Aug. 12, 2015

Nov. 27, 2013

Stockholders' Deficit (Textual)

Common stock, shares authorized

1,000,000,000

1,000,000,000

1,000,000,000

Preferred stock, shares authorized

100,000,000

100,000,000

100,000,000

Aggregate principal amount

$ 105,000

Common stock issued on conversion

90,000

Common stock issued for services

$ 31,689

Restricted common stock issued, Shares

600,000

Treasury stock, value

372,601

$ 367,531

Shares issued, price per share

$ 0.024

Issuance of common stock

$ 31,689

$ 36,769

Issuance of fair market value

Conversion of unpaid wages

$ 95,708

Common stock purchased by Investor

$ 90,000

$ 90,000

Common stock price percentage

90.00%

Selling and Marketing Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance

$ 30,000

General and Administrative Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance

$ 1,143

$ 547

$ 36,000

Series A Preferred stock [Member]

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Common stock issued for services, Shares

Common stock issued for services

Conversion of unpaid wages, Shares

Conversion of unpaid wages

Common stock issued for bonuses, Shares

Common stock purchased by Investor

Series B Preferred Stock [Member]

Stockholders' Deficit (Textual)

Preferred stock, shares authorized

30,000,000

30,000,000

Preferred stock, shares issued

Preferred Stock [Member]

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Preferred stock, shares authorized

30,000,000

30,000,000

100,000,000

Convertible price, description

A one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company.

Description of asset purchase agreement

Series A Shares are entitled to vote at a 15-1 ratio to Common Stock.

Allan Viernes [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

300,000

Shares issued, price per share

$ 0.024

Joe Andreae [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

130,000

Treasury stock, value

$ 3,120

Justin Braune [Member]

Stockholders' Deficit (Textual)

Shares issued during period

28,702,167

Kyle Tracey [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

130,000

Treasury stock, value

$ 1,170

Board of Directors [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

142,857

49,760

1,250,000

Shares issued, price per share

$ 0.008

$ 0.011

$ 0.024

Board of Directors [Member] | Michael Cook [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

1,250,000

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 3,000

Board of Directors [Member] | Kyle Tracey [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

2,083,333

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 50,000

Board of Directors [Member] | Kyle Tracey One [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

555,555

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 13,333

Employees [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

30,000

Treasury stock, value

$ 360

Benjamin Beaulieu [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

300,000

Shares issued, price per share

$ 0.024

Benjamin Beaulieu [Member] | Allan Viernes [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

30,000

Treasury stock, value

$ 420

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Intellectual Property (Textual)
Trademarks	$ 123,150	$ 123,150
Trademarks [Member]
Intellectual Property (Textual)
Trademarks	$ 123,150